BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 208 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is 0.67 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,933,096 | +0.6% | 555,522 | 0.0% | 1.21% | -58.1% |
| Q2 2023 | $3,910,875 | -15.6% | 555,522 | 0.0% | 2.88% | -35.7% |
| Q1 2023 | $4,633,053 | -31.0% | 555,522 | -5.1% | 4.48% | -20.0% |
| Q4 2022 | $6,718,027 | -18.9% | 585,194 | -33.9% | 5.60% | +19.1% |
| Q3 2022 | $8,284,000 | +17.6% | 885,194 | -7.2% | 4.71% | +119.9% |
| Q2 2022 | $7,046,000 | -75.9% | 953,994 | -58.0% | 2.14% | -63.0% |
| Q1 2022 | $29,242,000 | +19.2% | 2,270,733 | -4.2% | 5.78% | +65.9% |
| Q4 2021 | $24,523,000 | -11.7% | 2,370,733 | +14.5% | 3.48% | +0.8% |
| Q3 2021 | $27,777,000 | -8.5% | 2,070,733 | +7.8% | 3.46% | -17.4% |
| Q2 2021 | $30,367,000 | +26.1% | 1,920,733 | -18.9% | 4.18% | +16.1% |
| Q1 2021 | $24,079,000 | +8.4% | 2,367,670 | -20.6% | 3.61% | +29.6% |
| Q4 2020 | $22,207,000 | +156.0% | 2,980,870 | +18.0% | 2.78% | +143.5% |
| Q3 2020 | $8,676,000 | -9.0% | 2,525,857 | +26.3% | 1.14% | -5.5% |
| Q2 2020 | $9,530,000 | – | 2,000,000 | – | 1.21% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VHCP Management, LLC | 1,744,356 | $18,455,000 | 9.59% |
| RA Capital Management | 4,347,456 | $45,996,000 | 3.30% |
| Cormorant Asset Management, LP | 1,168,000 | $12,357,000 | 2.84% |
| Baker Brothers Advisors | 5,867,031 | $62,073,000 | 0.79% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 907,920 | $9,606,000 | 0.39% |
| QVT Financial LP | 525,734 | $5,562,000 | 0.32% |
| EAM Investors, LLC | 114,548 | $1,212,000 | 0.22% |
| FRANKLIN STREET ADVISORS INC /NC | 93,000 | $984,000 | 0.20% |
| THB ASSET MANAGEMENT | 301,529 | $3,190,000 | 0.19% |
| TPG Group Holdings (SBS) Advisors, Inc. | 1,162,269 | $12,297,000 | 0.13% |